Drug intelligence / Profile preview

Accusol

Development stage: Unknown
Lead developer: Takeda
Administration: Extracorporeal

Overview

Accusol is a solution utilized in Continuous Renal Replacement Therapy (CRRT). It was originally part of Baxter International's legacy CRRT business, which included the Aquarius CRRT System and associated disposables. Nikkiso America acquired this business, including Accusol, from Baxter International to expand its presence in the acute renal failure and intensive care unit (ICU) market.

Brand names: Accusol

Beyond the preview

Go deeper on Accusol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accusol.

Explore the full profile